Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | JAK1 | P23458 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 8/20 | 0.40 |
| ▸ | TYK2 | P29597 | 7/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662814 | 0.77 | JAK2 (0.53) | DAOJAK2JAK1JAK3TYK2 | |
| SCHEMBL1665156 | 0.71 | KDM4A (0.37) | DAOKDM5BKDM5A | |
| SCHEMBL1662359 | 0.70 | ADORA1 (0.40) | DAOJAK2JAK1JAK3TYK2 | |
| SCHEMBL1662466 | 0.70 | ADORA1 (0.37) | DAO | |
| Hydrochloric Acid SCHEMBL4715433 | 0.63 | KDM4E (0.59) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL21331825 | 0.58 | DAO (0.49) | DAOJAK2JAK1JAK3TYK2 | |
| SCHEMBL26686598 | 0.57 | GCK (0.50) | KDM5BKDM5A | |
| SCHEMBL27904995 | 0.57 | KMT2A (0.60) | DAOKDM5BKDM5AHTR3AHRH4 | |
| SCHEMBL12953106 | 0.56 | KDM5B (0.43) | DAOKDM5BKDM5AHTR3AHRH4 | |
| SCHEMBL26686492 | 0.56 | KDM5B (0.46) | DAOKDM5BKDM5AHTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | claimed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | claimed |
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
| EP-2490693-A1 | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049722-A1 | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | CDK1, CDK5, TTBK1 | DAO 2121/4885JAK2 799/4885JAK1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.